MC
BIO icon

Maverick Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Maverick Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,082
Closed -$1.48M – 416
2023
Q1 		$1.48M Buy
3,082
+2,447
+385% +$1.15M 0.04% 103
2022
Q4 		$267K Buy
+635
New +$256K 0.01% 315
2021
Q3 		– Sell
-273
Closed -$176K – 651
2021
Q2 		$176K Buy
273
+50
+22% +$30.4K ﹤0.01% 500
2021
Q1 		$127K Sell
223
-193
-46% -$114K ﹤0.01% 552
2020
Q4 		$243K Buy
+416
New +$237K ﹤0.01% 492
2020
Q3 		– Sell
-915
Closed -$413K – 580
2020
Q2 		$413K Buy
+915
New +$404K 0.01% 462

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return